VTYX Stock Summary and Trading Ideas (Ventyx Biosciences | NASDAQ:VTYX)

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Ventyx Biosciences trades on the NASDAQ stock market under the symbol VTYX.

As of January 30, 2026, VTYX stock price was flat at $13.95 with 993,970 million shares trading.

VTYX has a beta of 2.52, meaning it tends to be more sensitive to market movements. VTYX has a correlation of 0.15 to the broad based SPY ETF.

VTYX has a market cap of $1.00 billion. This is considered a Small Cap stock.

In the last 3 years, VTYX traded as high as $47.25 and as low as $.78.

The top ETF exchange traded funds that VTYX belongs to (by Net Assets): VTI, IBB, VXF, XPH, SCHA.

VTYX has outperformed the market in the last year with a price return of +580.5% while the SPY ETF gained +15.6%. VTYX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +65.7% and +0.4%, respectively, while the SPY returned +2.1% and 0.0%, respectively.

VTYX support price is $13.26 and resistance is $14.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTYX shares will trade within this expected range on the day.